Johnathan Matlock
Co-Founder @ Science Angel Syndicate
Bedford, United Kingdom
Johnathan Matlock is a seed investor at Science Angel Syndicate in Bedford focused on Medical and Biotechnology. Johnathan Matlock is Co-Founder Science Angel Syndicate.
- Total investments:
- 9
- Last investment:
- Lead investor:
- 56%
Last updated:
For AI agents: llms.txt
Industries Johnathan Matlock invests in
Stages Johnathan Matlock invests in
Countries Johnathan Matlock invests in
Round sizes
Round size
- Seed
- $1.3M–$6.1M
- Pre-Seed
- $1.1M–$1.1M
- Venture - Series Unknown
- $2.3M–$6M
Investment Focus
Industry
- Medical 4 (44%)
- Biotechnology 3 (33%)
- Health Care 2 (22%)
- Life Science 2 (22%)
- Robotics 1 (11%)
Stage
- Seed 5 (56%)
- Pre-Seed 1 (11%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Halo Therapeutics
|
Halo Therapeutics develops antivirals to prevent users from sickness. It researches on virus shapes and creates fatty acids into medicine to lock them. Halo Therapeutics was founded in 2020 and is based in Bristol, England. | $1.9M / Seed / May 17, 2023 | |
OSSTEC
|
OSSTEC is bringing advanced technology to the operating room with metal 3D printed bone healing implants. The orthopaedic implants emulate natural bone structure and address high failure rates of existing implants, keeping patients who suffer with osteoarthritis healthy, active and enjoying life. | $1.5M / Seed / Mar 30, 2023 | |
EnsiliTech
|
EnsiliTech is a biopharmaceuticals company that preserves the integrity of vaccines and other biological materials. | $1.1M / Pre-Seed / Jan 17, 2023 | |
|
EnsiliTech
|
EnsiliTech is a biopharmaceuticals company that preserves the integrity of vaccines and other biological materials. | $1.1M / Pre-Seed / Jan 17, 2023 | |
QV Bioelectronics
|
Time is precious and for patients with the most common brain tumour, glioblastoma, the value of that time really comes into focus when they are suddenly hit with the news there is no cure and that they have just one year to live. Current treatment options are not good enough and come at a huge cost to the quality of that remaining time. Ourco-founder Dr Richard Fu recognised this and was frustrated not only by the lack of treatments available for his brain tumour patients but also by major design flaws in newer electrotherapy approaches. Working together with Dr Chris Bullock, a biomedical engineer arising from Manchester's world-class materials research centres, they formed an elegant solution designed to optimise patient life-expectancy and quality of life. Together they formed QV Bioelectronics, and since then, their ground-breaking research has received over $425k in financial awards from several UK institutions, including Innovate UK and the National Institute for Health Research in the UK. The technology core patent has been filed, with full FTO. Additionally, alongside Dr Fu's expertise, the clinical advisory board contains some of Britain's top neurosurgeons who are helping to input into the feedback of the technology design. Our aim is to double patient life expectancy compared to standard treatment without impacting quality of life, so patients can focus on what matters. Join us at QV Bioelectronics, in pioneering a better option for terminal cancer patients. | $2.4M / Seed / Jan 10, 2023 | |
|
QV Bioelectronics
|
Time is precious and for patients with the most common brain tumour, glioblastoma, the value of that time really comes into focus when they are suddenly hit with the news there is no cure and that they have just one year to live. Current treatment options are not good enough and come at a huge cost to the quality of that remaining time. Ourco-founder Dr Richard Fu recognised this and was frustrated not only by the lack of treatments available for his brain tumour patients but also by major design flaws in newer electrotherapy approaches. Working together with Dr Chris Bullock, a biomedical engineer arising from Manchester's world-class materials research centres, they formed an elegant solution designed to optimise patient life-expectancy and quality of life. Together they formed QV Bioelectronics, and since then, their ground-breaking research has received over $425k in financial awards from several UK institutions, including Innovate UK and the National Institute for Health Research in the UK. The technology core patent has been filed, with full FTO. Additionally, alongside Dr Fu's expertise, the clinical advisory board contains some of Britain's top neurosurgeons who are helping to input into the feedback of the technology design. Our aim is to double patient life expectancy compared to standard treatment without impacting quality of life, so patients can focus on what matters. Join us at QV Bioelectronics, in pioneering a better option for terminal cancer patients. | $2.4M / Seed / Jan 10, 2023 | |
cheMastery
|
CheMastery is a company that creates laboratory automation technology. They provide automation solutions for chemical laboratories in order to facilitate the manufacturing and R&D processes in the chemical sector. It makes science more effective and reliable for scientists in the chemical sector. | Seed / Nov 13, 2022 | |
Zentraxa
|
Zentraxa’s proprietary technological platform, Zentide, combined with our extensive technical know-how allows us to push the boundaries of what can be achieved with synthetic biopolymers. We specialise in the design, production and testing of complex novel peptides and, as a result of our Zentide platform, can circumvent previously existingbio-design limits imposed by conventional peptide synthesis, with one universal process. | Seed / May 27, 2022 | |
|
Zentraxa
|
Zentraxa’s proprietary technological platform, Zentide, combined with our extensive technical know-how allows us to push the boundaries of what can be achieved with synthetic biopolymers. We specialise in the design, production and testing of complex novel peptides and, as a result of our Zentide platform, can circumvent previously existingbio-design limits imposed by conventional peptide synthesis, with one universal process. | Seed / May 27, 2022 |
Co-Investors
About Science Angel Syndicate
Science Angel Syndicate is a entrepreneurs and investors source world class scientific discoveries that impact society on a global scale.
Science Angel Syndicate Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Johnathan Matlock
Co-Founder
|
|||
4 more contacts available
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Johnathan Matlock invest in?
Johnathan Matlock invests primarily in Medical, Biotechnology and Health Care startups, most often at Seed and Pre-Seed stage. Most of the 9 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Johnathan Matlock's check size?
Johnathan Matlock typically joins rounds of $1.3M–$6.1M at Seed, $1.1M–$1.1M at Pre-Seed and $2.3M–$6M at Venture - Series Unknown. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Johnathan Matlock participates in.
When did Johnathan Matlock last invest?
The most recent investment recorded for Johnathan Matlock closed in May 2023. Shizune tracks 9 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
